Literature DB >> 29879366

Anticipating Industry Arguments: The US Food and Drug Administration's Authority to Reduce Nicotine Levels in Cigarettes.

Micah L Berman1, Patricia J Zettler2, David L Ashley3.   

Abstract

The US Food and Drug Administration has announced that it is considering lowering nicotine levels in cigarettes to "minimally addictive or nonaddictive levels." This could be a transformative public health measure, but the tobacco industry is likely to challenge such an action in court. This article reviews some of the key legal arguments that industry is likely to advance and considers possible responses. As we demonstrate, there are strong arguments that the US Food and Drug Administration has the authority to implement a policy to reduce nicotine in cigarettes to nonaddictive levels.

Entities:  

Keywords:  FDA; addiction; law/legal issues; nicotine; public policy; tobacco

Mesh:

Substances:

Year:  2018        PMID: 29879366      PMCID: PMC6055287          DOI: 10.1177/0033354918776935

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  14 in total

1.  Smoking in the absence of nicotine: behavioral, subjective and physiological effects over 11 days.

Authors:  Eric C Donny; Elizabeth Houtsmuller; Maxine L Stitzer
Journal:  Addiction       Date:  2007-02       Impact factor: 6.526

2.  Effects of cigarette nicotine content and smoking pace on subsequent craving and smoking.

Authors:  Jesse Dallery; Elisabeth J Houtsmuller; Wallace B Pickworth; Maxine L Stitzer
Journal:  Psychopharmacology (Berl)       Date:  2002-10-31       Impact factor: 4.530

3.  A Nicotine-Focused Framework for Public Health.

Authors:  Scott Gottlieb; Mitchell Zeller
Journal:  N Engl J Med       Date:  2017-08-16       Impact factor: 91.245

4.  Chemical Characterization of Mainstream Smoke from SPECTRUM Variable Nicotine Research Cigarettes.

Authors:  Yan S Ding; Patricia Richter; Bryan Hearn; Liqin Zhang; Roberto Bravo; Xizheng Yan; Jose J Perez; Michele Chan; Jared Hughes; Patrick Chen; Wayne Chen; Joshua Wong; Sydney Holmberg; Shakia Smith; Morgan Larango; Liza Valentín-Blasini; Clifford H Watson
Journal:  Tob Regul Sci       Date:  2017-01-01

Review 5.  A nicotine delivery device without the nicotine? Tobacco industry development of low nicotine cigarettes.

Authors:  J Dunsby; L Bero
Journal:  Tob Control       Date:  2004-12       Impact factor: 7.552

6.  Pharmacodynamic effects of new de-nicotinized cigarettes.

Authors:  W B Pickworth; R V Fant; R A Nelson; M S Rohrer; J E Henningfield
Journal:  Nicotine Tob Res       Date:  1999-12       Impact factor: 4.244

7.  Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette.

Authors:  Arthur L Brody; Mark A Mandelkern; Matthew R Costello; Anna L Abrams; David Scheibal; Judah Farahi; Edythe D London; Richard E Olmstead; Jed E Rose; Alexey G Mukhin
Journal:  Int J Neuropsychopharmacol       Date:  2008-08-18       Impact factor: 5.176

8.  Characterization of SPECTRUM Variable Nicotine Research Cigarettes.

Authors:  Patricia Richter; Pappas R Steven; Roberto Bravo; Joseph G Lisko; Maria Damian; Nathalie Gonzalez-Jimenez; Naudia Gray; Lisa M Keong; Jacob B Kimbrell; Peter Kuklenyik; Tameka S Lawler; Grace E Lee; Magaly Mendez; Jose Perez; Shakia Smith; Hang Tran; Robert Tyx; Clifford H Watson
Journal:  Tob Regul Sci       Date:  2016

9.  Tobacco industry manipulation of data on and press coverage of the illicit tobacco trade in the UK.

Authors:  A Rowell; K Evans-Reeves; A B Gilmore
Journal:  Tob Control       Date:  2014-03-10       Impact factor: 7.552

10.  Illicit trade, tobacco industry-funded studies and policy influence in the EU and UK.

Authors:  Gary Jonas Fooks; Silvy Peeters; Karen Evans-Reeves
Journal:  Tob Control       Date:  2013-01-15       Impact factor: 7.552

View more
  1 in total

1.  Nicotine Reduction in Cigarettes: Literature Review and Gap Analysis.

Authors:  Micah L Berman; Allison M Glasser
Journal:  Nicotine Tob Res       Date:  2019-12-23       Impact factor: 4.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.